By Delilah Alvarado | BioPharma Dive
Published: October 12, 2026
In a significant development for the immunology landscape, biotechnology firm First Tracks announced positive early-stage clinical trial results for its lead drug candidate, ANB033. The experimental therapy, designed to target the underlying immune mechanisms of celiac disease, has generated substantial optimism among industry analysts, with some characterizing the asset as having "pipeline-in-a-product" potential. Following the disclosure of the data on Monday, the company’s stock price surged approximately 7%, reflecting investor confidence in the potential for a first-in-class therapeutic breakthrough.
The Challenge of Celiac Disease
Celiac disease remains a pervasive and largely undertreated immune-mediated condition. When an individual with celiac disease consumes gluten—a protein found in wheat, barley, and rye—the immune system launches an aberrant response, mistakenly attacking the lining of the small intestine. Over time, this chronic inflammation leads to the destruction of the intestinal villi, causing severe malabsorption of essential vitamins and minerals.
For decades, the standard of care has been limited to a strict, lifelong gluten-free diet. While effective for symptom management in many, the diet is notoriously difficult to maintain and does not fully address the underlying autoimmune pathology for all patients. Consequently, the medical community has long sought a pharmacological intervention that could provide a "safety net" for accidental gluten exposure or address the systemic inflammation that persists despite dietary compliance. As Monique da Silva, First Tracks’ senior vice president of corporate affairs, noted, "Celiac disease is the largest autoimmune disease without an approved treatment."
Chronology: A Competitive Race in the Immunology Space
The race to develop the first FDA-approved medication for celiac disease has intensified over the past two years, with several major players vying for dominance.
- Early 2025: Teva Pharmaceuticals and Argenx escalate their efforts, committing significant capital toward clinical programs targeting the IL-15 pathway, a key mediator in celiac-related intestinal damage.
- September 2026: Teva Pharmaceuticals releases promising early-stage data regarding their targeted celiac candidate, which demonstrates a reduction in gluten-induced intestinal inflammation.
- Early October 2026: Market anticipation builds as First Tracks prepares to release the initial readout from their Phase 1/2 study of ANB033.
- October 12, 2026: First Tracks officially reports that ANB033 met primary endpoints, triggering a positive market reaction and prompting favorable comparisons to competitor data.
The landscape is defined by a common strategy: targeting specific receptors and proteins involved in the immune response to gluten. While Teva focuses specifically on inhibiting IL-15, First Tracks’ ANB033 takes a slightly broader approach by blocking the CD122 receptor. CD122 is a critical component used by two potent immune-regulating proteins, IL-2 and IL-15. By inhibiting this receptor, ANB033 aims to dampen the overactive immune response at its source. Argenx, following a recent strategic acquisition, is also pursuing a CD122-targeting therapy, placing them in direct competition with First Tracks’ clinical trajectory.
Supporting Data: Dissecting the ANB033 Trial
The data released by First Tracks on Monday represents a critical milestone. The study enrolled 32 participants, all diagnosed with celiac disease, who were randomized into a control group receiving a placebo or an experimental group receiving three subcutaneous doses of ANB033 over a four-week period.
Following the dosing regimen, participants underwent a rigorous two-week "gluten challenge," in which they consumed an amount of gluten equivalent to two slices of bread per day. In a healthy individual, this would be trivial; for a celiac patient, this typically induces a marked inflammatory response.
The results were compelling: ANB033 achieved statistical significance on three distinct biological measures assessing the severity of the inflammatory reaction in the small intestine. Perhaps more importantly for future regulatory approval, the drug demonstrated a "clean safety" profile, with no significant adverse events reported during the study duration. Leerink Partners analyst David Risinger, in a note to clients, described the findings as "impressive," noting that while head-to-head trials have not been conducted, the preliminary efficacy data for ANB033 compares "favorably" to the results recently disclosed by Teva.
Official Perspectives and Corporate Strategy
The implications of these results extend far beyond the immediate celiac market. First Tracks is positioning ANB033 as a versatile therapeutic agent. Because the CD122 pathway is implicated in a variety of autoimmune and inflammatory conditions, the company is aggressively expanding its clinical footprint.
"We view ANB033 as having pipeline-in-a-product potential across several autoimmune diseases," Risinger wrote. The company’s development plan reflects this ambition:
- Eosinophilic Esophagitis (EoE): A Phase 1b trial is currently underway, with top-line data anticipated in the third quarter of 2027.
- Vitiligo: First Tracks is on track to initiate Phase 2 development for this skin condition in the first half of 2027.
- Undisclosed Indication: The company has hinted at a third, unnamed autoimmune indication, which is also slated for Phase 2 entry in early 2027.
Monique da Silva emphasized that the goal is not to replace the gluten-free diet, but to augment it. "Should these early results be confirmed in larger, late-stage trials, the drug could offer people with the condition a new layer of protection," she stated. This "protection" would be life-changing for patients, potentially mitigating the long-term health risks associated with accidental gluten ingestion, such as refractory celiac disease or, in rare cases, intestinal lymphoma.
Implications for the Future of Autoimmune Therapy
The success of ANB033 serves as a bellwether for the broader biotech sector. For years, the development of drugs for autoimmune disorders has been characterized by high failure rates, particularly in diseases where the exact trigger is complex and multifaceted. By successfully navigating a gluten challenge in a clinical setting, First Tracks has validated its methodology and provided a clear roadmap for other companies to follow.
However, challenges remain. The transition from early-stage success to Phase 3 success is fraught with hurdles, including the need to demonstrate long-term safety and durable efficacy. As the clinical trials progress, regulators will likely demand larger, multi-center studies to confirm that the biological markers observed in the initial 32-patient cohort translate into meaningful, long-term clinical benefits for a broader, more diverse patient population.
Moreover, the competitive environment remains fierce. With Argenx and Teva also advancing their candidates, the first company to reach the finish line will likely capture a significant portion of the market share. The ability of First Tracks to maintain its momentum, secure funding for the upcoming Phase 2 and 3 trials, and effectively manage its multi-indication pipeline will be the defining factors in its long-term success.
For the millions of people living with celiac disease, the news from First Tracks offers a rare glimmer of hope. While a cure remains elusive, the prospect of a targeted biological therapy that can suppress the immune system’s overreaction to gluten represents the most promising shift in the treatment landscape in decades. As the industry looks toward the next set of data in 2027, the focus will remain on whether ANB033 can deliver on its promise to transform a life of dietary restriction into a life of medical management and improved patient outcomes.
About the Author
